Business
InvestmentPitch Media Video Discusses Voyageur Pharmaceuticals' MOU with Summit Nanotech to Develop Iodine Extraction Technology and Additions to Scientific Advisory Board - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - November 9, 2021) - Voyageur Pharmaceuticals (T...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"InvestmentPitch Media Video Discusses Voyageur Pharmaceuticals' MOU with Summit Nanotech to Develop Iodine Extraction Technology and Additions to Scientific Advisory Board - Video Available on Investmentpitch.comVancouver, British Columbia--(Newsfile Corp. - November 9, 2021) - Voyageur Pharmaceuticals (TSXV: VM) (OTC Pink: VYYRF) has signed a non-binding Memorandum of Understanding with Summit Nanotech Corporation. Under the MOU, the companies plan to develop a more sustainable process for the production of iodine medical products used as contrast agents, by leveraging Summit's award winning lithium extraction technology.For more information, please view the InvestmentPitch Media \"video\" which provides additional information about this news and the company. If this link is not enabled, please visit www.InvestmentPitch.com and enter \"Voyageur\" in the search box.Cannot view this video? Visit:http://www.investmentpitch.com/video/1_fvy0gvlz/Voyageur-Pharmaceuticals-signs-MOU-with-Summit-Nanotech-to-develop-iodine-extraction-technology-and-completes-additions-to-scientific-advisory-boardThere have been no significant advancements in processing technology in over 20 years in the compounding of iodine medical products. Summit's innovative nanomaterials have the potential to decrease production costs and increase production efficiency, while also creating a lower environmental footprint. By collaborating with Summit and operating a \"green\" pharmaceutical manufacturing process, Voyageur will contribute to a reduction in worldwide carbon emissions and ensure that their long-term goals align with the United Nations Agenda 2030 Sustainable Development Plan.Voyageur develops, manufactures and will commercialize high-performance cost-effective imaging contrast agents for the medical radiology marketplace. Brent Willis, CEO of Voyageur, stated: \"By joining with SNT, we are fortifying our concept of fully integrating our operations from earth to bottle. Manufacturing contrast agents that we control at costs that are lower than those of other iodine producers, will enable Voyageur to gain a competitive edge in the marketplace and help to reduce healthcare costs worldwide.\"Amanda Hall, CEO of Summit Nanotech, added: \"Voyageur's holistic approach of mineral extraction from underground brines for iodine, using sustainable processes, align...